Contrasting Entrada Therapeutics (NASDAQ:TRDA) & MDxHealth (NASDAQ:MDXH)

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Entrada Therapeutics and MDxHealth”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entrada Therapeutics $3.98 million 50.11 -$143.75 million ($3.84) -1.33
MDxHealth $114.02 million 0.06 -$33.52 million ($0.75) -0.19

MDxHealth has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Entrada Therapeutics has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Entrada Therapeutics and MDxHealth, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics 1 2 4 0 2.43
MDxHealth 1 4 1 0 2.00

Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 248.72%. MDxHealth has a consensus target price of $1.33, indicating a potential upside of 825.28%. Given MDxHealth’s higher probable upside, analysts plainly believe MDxHealth is more favorable than Entrada Therapeutics.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Entrada Therapeutics and MDxHealth’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entrada Therapeutics -4,057.98% -64.00% -50.49%
MDxHealth -40.84% N/A -27.78%

Summary

MDxHealth beats Entrada Therapeutics on 9 of the 14 factors compared between the two stocks.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

About MDxHealth

(Get Free Report)

MDxHealth is a molecular diagnostics company focused on tests that support the detection and management of urologic cancers, particularly prostate cancer. Its services are intended to help clinicians assess cancer risk and make more informed decisions about biopsies and treatment. The company’s products include SelectMDx, a urine-based test that helps assess the risk of clinically significant prostate cancer, and ConfirmMDx, a tissue-based test that can help guide decisions after a negative prostate biopsy.

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.